Enkephalin

JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain

Retrieved on: 
Tuesday, August 29, 2023

LAS VEGAS, Aug. 29, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the visionary biotech company dedicated to discovering non-addictive treatments for pain, as well as causes of pain, has earned a US patent for its innovative formulation of low-dose naltrexone, Jan123, for treating pain.

Key Points: 
  • Jan123 is being developed to treat complex regional pain syndrome (CRPS), a rare and often life-altering condition characterized by severe pain and hypersensitivity to touch.
  • "Today, patients with complex regional pain syndrome must resort to long-term opioid and narcotics for relief," Isaac said.
  • Dr. Amol Soin, the inventor of Jan123 and its novel uses, expressed great satisfaction with the US Patent Office's action.
  • "All in all," CEO Isaac concluded, "this patent approval is an important milestone in our company's brief history—and a welcome confirmation of our strategic vision."

IACTA Pharmaceuticals Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclinical Studies of IC 800 to Treat Pain Relief for Eye Injury

Retrieved on: 
Thursday, October 28, 2021

A very significant and immediate result of eye trauma is acute pain, which frequently evolves into chronic pain.

Key Points: 
  • A very significant and immediate result of eye trauma is acute pain, which frequently evolves into chronic pain.
  • IC 800 uses IACTAs proprietary DENKI molecule to inhibit enzymes that degrade the bodys natural response to pain.
  • I am delighted to have the support of the U.S. Department of Defense as IACTA advances IC 800 for the treatment of ocular pain.
  • Opinions, interpretations, conclusions and recommendations are those of IACTA Pharmaceuticals and are not necessarily endorsed by the Department of Defense.

Virpax Pharmaceuticals Engages Torreya Capital to Advise on Global Partnering Efforts

Retrieved on: 
Thursday, April 22, 2021

Our partners are senior industry bankers and executives with deep experience, knowledge, and networks.

Key Points: 
  • Our partners are senior industry bankers and executives with deep experience, knowledge, and networks.
  • We are a partner of choice for companies seeking discreet, conflict-free, and knowledgeable advice on M&A, capital markets, licensing, and asset sale transactions.
  • Torreya is differentiated from most other life sciences advisory practices by the breadth of its global presence.
  • Envelta\xe2\x84\xa2 is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer.

DGAP-News: Virpax(R) Pharmaceuticals Inc.: Virpax Begins IND Enabling Studies of Envelta(TM)

Retrieved on: 
Tuesday, February 23, 2021

Anthony P. Mack, Chairman and CEO of Virpax stated, "The commencement of these critical pre-clinical studies takes us one step closer to the clinic.

Key Points: 
  • Anthony P. Mack, Chairman and CEO of Virpax stated, "The commencement of these critical pre-clinical studies takes us one step closer to the clinic.
  • Dr. Jeffrey Gudin, principal investigator and co-founder of Virpax, has been working in partnership with the NCATS since we announced the CRADA in August 2020.
  • Envelta(TM) is an intranasal enkephalin drug product candidate formulation based on nanotechnology which enables the delivery of the drug product to the brain.
  • Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery.